## UNITED STATES PATENT AND TRADEMARK OFFICE

BEFORE	THE	PATENT	TRIAL	AND	<b>APPEAL</b>	BOARD

APOTEX INC., APOTEX CORP., ARGENTUM PHARMACEUTICALS LLC, ACTAVIS ELIZABETH LLC, TEVA PHARMACEUTICALS USA, INC., SUN PHARMACEUTICAL INDUSTRIES, LTD., SUN PHARMACEUTICAL INDUSTRIES, INC., AND SUN PHARMA GLOBAL FZE,

Petitioners,

V.

NOVARTIS AG,

Patent Owner.

Case IPR2017-00854<sup>1</sup>

U.S. Patent No. 9,187,405

**DECLARATION OF CHRISTIAN SCHNELL** 

Mail Stop Patent Board Patent Trial and Appeal Board U.S. Patent and Trademark Office P.O. Box 1450 ALEXANDRIA, VA 22313-1450



<sup>&</sup>lt;sup>1</sup> Cases IPR2017-01550, IPR2017-01946, and IPR2017-01929 have been joined with this proceeding.

I, Christian Schnell, declare as follows:

1. I am an inventor listed on U.S. Patent No. 9.187,405, the subject of
these inter-partes review (IPR) proceedings. I am currently employed by Novartis
Pharma AG, a subsidiary of Patent Owner Novartis AG in these proceedings. I
submit this declaration to authenticate Exhibits 2057, a May 12, 2009 internal
Novartis report and 2070, a two-
page signature sheet that confirms the report's completion.

4. I retrieved a copy of Exhibit 2057 from Novartis's internal system used to keep track of such documents, and I confirm that it is a true and accurate



copy of the report we prepared in 2009. In addition, Exhibit 2070 was also filed in the same system. It is common for the signature pages for final reports to be filed separately from the main report in our system. I confirmed that this is the signature page that I remember going with this report.

\* \*

- 5. Under penalty of perjury, all statements made herein of my own knowledge are true, and I believe all statements made herein on information and belief to be true. I have been warned and am aware that willful false statements and the like are punishable by fine or imprisonment or both under Section 1001 of Title 18 of the United States Code.
- 6. In signing this Declaration, I understand that it will be filed as evidence in a contested case before the Patent Trial and Appeal Board of the United States Patent and Trademark Office. I acknowledge that I may be subject to cross-examination in the case and that cross-examination will take place in the United States. If cross-examination is required of me, I will appear for cross-examination within the United States during the time allotted.

	_		
DATED: November 10, 2017	By:		
		hristian Schnell	

